Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Aetna Inc    AET

AETNA INC (AET)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Goldman M&A head Sykes joins management committee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/19/2012 | 11:07pm CET

Gene Sykes, global head of Goldman Sachs Group Inc's (>> Goldman Sachs Group, Inc.) mergers and acquisitions business, has been named to the investment bank's management committee, according to an internal memo.

Gene Sykes, global head of Goldman Sachs Group Inc's (>> Goldman Sachs Group, Inc.) mergers and acquisitions business, has been named to the investment bank's management committee, according to an internal memo.

The 54-year-old investment banker joins 28 other executives on the powerful committee, which includes Chief Executive Lloyd Blankfein and Chief Operating Officer Gary Cohn, and influences decisions about Goldman's business strategy and operations.

Sykes' appointment comes just nine days after the departure of another prominent Goldman banker, Yoel Zaoui, was announced in a separate internal memo. Zaoui shared the title of M&A co-head with Sykes and had also been on the management committee.

Sykes, who is based in Los Angeles, is also chairman of the global technology, media and telecommunications department of the investment banking division. He is a member of Goldman's internal Business Standards Committee.

The Goldman veteran joined the firm in 1984 and became a partner in 1992. He has advised on several high-profile deals, including Walt Disney Co's (>> The Walt Disney Company) acquisition of Pixar, Aetna Inc's (>> Aetna Inc.) acquisition of U.S. Healthcare and Roche Holding AG acquisition of Genentech.

"Gene has played a vital role in strengthening our investment banking franchise, particularly with respect to many of the most significant companies in technology and media," Blankfein and Cohn said in the memo, whose contents were confirmed by a spokesman.

(Reporting By Lauren Tara LaCapra in New York; editing by Andre Grenon)

By Lauren Tara LaCapra

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AETNA INC
11/22 AETNA : The Family Conversation You Need to Have on the Menu for Thanksgiving
11/22 Prospect of tougher antitrust regulation worries deal investors
11/21DJAETNA : Fear of Tech Giants Fuels Deal Boom -- WSJ
11/20 REPORT : Buyout of Aetna Inc. Could Come This Month
11/20DJCVS HEALTH : Takeovers Roar to Life as Companies Hear Footsteps From Tech Giants
11/20 AETNA : and VCU Health System announce new agreement for Medicare members
11/17 AETNA : County to extend deadline for retirees considering Medicare supplement i..
11/15 AETNA : Better Health® of Louisiana to Host Family Fall Festival on Nov. 20
11/14 AETNA : Introducing Aetna Better Health® of Maryland
11/13 AETNA : and Baptist Health Medical Group announce new agreement for Medicare mem..
More news
News from SeekingAlpha
11/23 Tracking Larry Robbins' Glenview Capital Management Portfolio - Q3 2017 Updat..
11/20 Aetna perks up 1% on report that CVS takeover imminent
11/17 40 Dividend Stocks Battling Into 2018
11/15 Buy Idexx Laboratories While It's Down - Cramer's Lightning Round (11/14/17)
11/13 CVS Dividend Remains Safe - Q3 2017 Update
Financials ($)
Sales 2017 60 653 M
EBIT 2017 4 637 M
Net income 2017 2 321 M
Debt 2017 -
Yield 2017 0,95%
P/E ratio 2017 24,46
P/E ratio 2018 18,50
Capi. / Sales 2017 0,95x
Capi. / Sales 2018 0,95x
Capitalization 57 472 M
Chart AETNA INC
Duration : Period :
Aetna Inc Technical Analysis Chart | AET | US00817Y1082 | 4-Traders
Technical analysis trends AETNA INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 184 $
Spread / Average Target 4,2%
EPS Revisions
Managers
NameTitle
Mark T. Bertolini Chairman & Chief Executive Officer
Karen S. Lynch President
Margaret M. McCarthy Executive Vice President-Operations & Technology
Shawn M. Guertin CFO, Executive VP & Chief Enterprise Risk Officer
Harold L. Paz Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AETNA INC42.12%57 472
UNITEDHEALTH GROUP31.98%204 220
ANTHEM INC53.31%56 595
CIGNA CORPORATION50.48%49 487
HUMANA INC16.80%34 044
CENTENE CORP71.56%16 730